Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes

Area of Science:

• Immunology
• Endocrinology
• Clinical Trials

Background:

• CD8+ T regulatory (Treg) cells recognizing Qa-1/human leukocyte antigen E (Q/E) are crucial for self-tolerance.
• Investigating the role of Q/E CD8+ Treg cells in type 1 diabetes (T1D) pathogenesis is essential.
• Exploring interventions targeting Q/E CD8+ Treg cells may offer a novel approach to delay T1D progression.

Purpose of the Study:

• To assess the safety and efficacy of autologous dendritic cell therapy (AVT001) in individuals with T1D.
• To investigate the potential of AVT001 in preserving pancreatic beta-cell function.
• To evaluate the impact of AVT001 on glycemic control and insulin requirements in T1D patients.

Main Methods:

• A phase 1/2, randomized, double-blind, placebo-controlled trial was conducted.
• Participants (≥16 years) were within 1 year of T1D diagnosis and had a Q/E CD8+ Treg function defect.
• Patients received AVT001 or placebo via monthly intravenous infusions for safety and efficacy endpoints, including C-peptide AUC, HbA1c, and insulin dose.

Main Results:

• AVT001 was well-tolerated with no serious adverse events reported through day 360.
• Treatment with AVT001 demonstrated a statistically significant preservation of C-peptide area under the curve (AUC) compared to placebo at 150 and 360 days.
• No significant differences were observed between AVT001 and placebo groups in changes in HbA1c or insulin dose.

Conclusions:

• AVT001 exhibited a favorable safety profile in this phase 1/2 trial, with no dose-limiting adverse events.
• Preliminary efficacy signals suggest AVT001 may preserve beta-cell function in T1D patients.
• Further evaluation in a fully powered clinical trial is warranted to confirm these findings.